Objective: Explicit reporting of absolute measures is important to ensure treatment effects are correctly interpreted. We examined the extent to which authors report absolute effects for patient-important outcomes in abstracts of systematic review.
Introduction
Readers of the medical literature often first refer the abstract of a systematic review (SR) to judge the magnitude of results, including the point estimates for benefit and harm and their associated confidence intervals [1] , and may, due to limited access to full-text journals and time constraints, rely solely on abstracts. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses' (PRISMA's) reporting guidelines for abstracts recommend that results for the main outcomes of both benefits and harms should be reported as part of the synthesis of the results, preferably providing the number of studies and participants for each included outcome, the summary measures (estimates) and the corresponding measure of precision [2] . The guidelines encourage the inclusion of information on the direction and size of effect in both absolute and relative measures [2] .
Including measures of absolute effects is particularly important for clinical decision-making. Expressing treatment effects in relative terms yields apparently larger treatment effects than if absolute terms are used (for example, a 50% relative risk reduction can mean an absolute risk reduction of 1% -i.e. 2% to 1%), and this difference influences the judgement of clinicians and patients regarding the treatment options [3] . Relative measures may also exaggerate small between-group differences for uncommon events and may minimize large differences for common events. Thus, exclusively presenting measures of relative effect without absolute measures can be misleading, and present further challenges to patients and clinicians attempting to trade off between desirable and undesirable effects [4] [5] [6] [7] . Recent guidelines by the Cochrane Collaboration have also recommended that review authors report estimates of absolute effects in their study abstracts, and acknowledged that they are more easily interpretable than relative effects [8] .
Although there is a high concordance between abstract and full-text article reporting of single primary outcomes in RCTs published in top medical journals, little is known about the extent to which abstracts of SRs report the most patient-important outcomes of benefit and harm and the extent to which abstracts report absolute measures of effect [9] . Considering that health care professionals often rely upon study abstracts for decision-making, we examined the extent to which authors reported absolute effects on patient-important outcomes in the abstracts of Cochrane and nonCochrane reviews reporting dichotomuous outcomes.
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Methods

Objectives
1. To examine the extent to which the most patient-important outcomes are reported in the full-texts and abstracts of Cochrane and non-Cochrane reviews 2. As judged from abstracts alone, to examine the use of explicit reporting of patient-important outcomes 3. As judged from abstracts alone, to examine the extent to which absolute effects are reported for patient-important outcomes 4. To examine the extent to which the most patient-important outcomes are reported in the full-texts and plain language summaries of Cochrane reviews.
Search strategy
Based on a publically available study protocol [10] which we modified to include a focus on abstract reporting of patient-important outcomes, we searched OVID Medline and the Cochrane Database of Systematic Reviews to identify eligible SRs published in the year 2010. An adapted version of the SR filter designed by the McMaster University Health Information Research Unit was used to retrieve non-Cochrane SRs, and Cochrane SRs using the "search by journal" option. Citations were exported into DistillerSR (Evidence Partners, Ottawa, ON, Canada).
Study selection and data extraction
A sample of 2,328 studies was identified by our search. Following the removal of duplicates, 2,278 studies were stratified into two groups: Cochrane and non-Cochrane reviews. Within each stratum, repeated random sampling in a 1:1 ratio was used in a iterative process, where pairs of reviewers independently screened studies at the title and abstract and full-text levels from both strata. A sample size of 202 SRs was obtained, of which 12 SRs were further deemed ineligible, leaving 190 eligible SRs. We included studies described as 'systematic review' or 'meta-analysis' that: 1) were published in English; 2) reported a search strategy in at least one database; 3) included a comparison of at least two interventions in humans; 4) reported at least one dichotomous outcome; 5) included at least one randomised controlled trial (RCT); and 6) included only RCTs as primary studies. SRs which only included primary outcomes of harm with no patient-important outcomes of benefit were excluded.
Among eligibile SRs, pairs of reviewers selected and extracted data on the population, intervention(s), comparator(s) and the most patient-important outcomes of benefit and harm. Each team of extractors consisted of one more experienced reviewer and one less experienced reviewer. Pre-tested and standardized forms with extensive M A N U S C R I P T
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instructions were used for eligibility screening, outcome selection and data abstraction, and any discrepant judgements between reviewers were resolved by consensus, or, if necessary, by a third reviewer. Each reviewer team completed calibration exercises before all screening and abstraction phases, to further ensure reliability.
The relative patient-importance of outcomes was guided by a hierarchy (Table 1) . Mortality (category I), morbidity (category II) and symptoms/quality of life/functional status (category III) were considered patient-important, while surrogate outcomes (category IV) were not. Categories I and II were considered "critically important", whereas category III was considered "important".
If outcomes of harm or benefit reported by a trial were equally important, the outcome with the largest number of observations was chosen. For composite outcomes, the component of greatest patient importance was selected. When the necessary disaggregated data for a composite outcome of interest was unavailable, we chose the next outcome of greatest patient-importance that was reported.
Data abstractors documented the reporting of absolute and relative treatment measures of effect for all eligible review abstracts, and if authors used explicit or implicit statements when reporting the most patient-important outcome of benefit and harm. We defined explicit reporting as a direct statement for a specific outcome with an absolute or relative numerical measure. For example, the following statement would be considered explicit reporting: "In the five studies, 143 people allocated to calcium had a myocardial infarction compared with 111 allocated to placebo (hazard ratio 1.31, 95% confidence interval 1.02 to 1.67, P=0.035) ." We defined implicit reporting as either a broad or indirect reference to the specific outcome, or lacking an absolute or relative numeric measure. For example, the following statement would be considered implicit reporting: "In the five studies, serious harms were associated with calcium compared to placebo". As a secondary outcome, we documented the proportion of abstracts and Cochrane plain language summaries that reported the beneficial and harmful outcomes judged as most patient-important from the full-text.
Absolute measures of interest included the absolute risk reduction (ARR) or risk difference (RD), and number needed to treat (NNT), and the proportion of beneficial or harmful events per group. Relative measures of interest included relative risk or rate ratio (RR), odds ratio (OR), hazard ratio (HR), and relative risk reduction (RRR). As some included studies reported both absolute and relative measures in their abstracts, it was noted that the number of measures reported exceeded the number of included studies. We calculated the chance-corrected agreement between reviewers regarding whether an absolute effect estimate was reported for the outcome of interest, and interpreted the results according to guidelines proposed by Landis and Koch [11] . Agreement of 0.01-0.20 was considered as slight, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1.00 as very good.
All data analyses were performed using SPSS statistical software, version 18.0 (SPSS Inc., Chicago, IL, USA).
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Results
We identified 2,278 potentially eligible articles after removal of duplicates. Following stratification between Cochrane and non-Cochrane SRs, repeated random sampling in a 1:1 ratio and initial title and abstract screening, 487 articles were deemed eligible for full-text review, of which 202 proved eligible. Twelve SRs were subsequently excluded, having only reported a harm-related outcome without an eligible outcome of benefit or due to study design, leaving 190 eligible SRs (96 Cochrane and 94 nonCochrane) ( Figure 1 ).
The 190 eligible reviews included a median of 5 RCTs (IQR: 2-9), a median number of 851 patients (IQR: 225-2108), and a median of 111.5 events for the outcome of interest (IQR: 31.5-391). Of the 190 reviews, 141 (74.2%) included a focus on a medical area and 55 (29.0%) on a surgical area, with 6 (3.2%) studies including a focus on both areas. The primary outcome represented a benefit in 172 (90.5%) of the reviews and harm in the remaining 18 (9.5%). In 135 (71.1%) of eligible SRs, the primary outcome chosen by the SR investigators was considered patient-important (Tables 2 and 3) .
Reporting of outcomes of benefit in the abstract
Of 190 SRs, 144 (75.8%) reported the outcome of benefit we judged most patient-important from the full-text in the abstract. Five (2.6%) reported only a composite outcome in the abstract despite reporting disaggregated data in their full-text. Thirty-one (16.3%) SRs did not report any of outcomes of benefit in their abstract. Results were similar between Cochrane and non-Cochrane SRs (p=0.91) ( Table 4 ).
As judged from abstract reporting alone, 161 (84.7%) abstracts reported a patient-important outcome of benefit. Of these, 121 (75.2%) abstracts provided an explicit statement, and 40 (24.8%) provided an implicit statement. Twenty-nine SRs (15.3%) did not report an important outcome of benefit in their abstract. No significant differences were observed between Cochrane and non-Cochrane SRs (Table 4) .
One hundred and twenty-seven (66.8%) SRs reported a total of 151 absolute and/or relative measures in their abstracts, of which 117 (77.5%) were relative measures and 34 (22.5%) were absolute measures. Eighteen (9.5%) abstracts provided both relative and absolute measures, with ARR/RD combined with RR (n=4) and rate of events per group combined with RR (n=6) being the most common combinations reported. No significant differences were observed between Cochrane and nonCochrane SRs (Table 4) .
Reporting of outcomes of harm in the abstract
Of 190 SRs, 73 (38.4%) reported critically important outcomes of harm in the fulltext. Of these, 46 (63.0%) reported this outcome in the abstract. Of our 190 SRs, 97 (51.1%) reported important outcomes of harm in the full-text. Of these, 67 (69.1%) reported this outcome in the abstract. No significant differences were observed between Cochrane and non-Cochrane SRs for critically important or important outcomes of harm (p=0.13) ( Table 5 ).
As judged from abstract reporting alone, 87 (45.8%) abstracts reported a patientimportant outcome of harm. Of those, an explicit statement was provided in 36 (41.4%) SRs, while an implicit statement was provided in 51 (58.6%) SRs. No significant differences were observed between Cochrane and non-Cochrane SRs (Table 5 ).
Forty-two (22.1%) SRs reported a total of 47 absolute and/or relative measures in their abstracts, of which 41 (87.2%) were relative measures and only 6 (12.8%) were absolute measures. Only two (1.1%) abstracts provided both a relative measure (OR and RR) and an absolute measure (ARR/RD). No significant differences were observed between Cochrane and non-Cochrane SRs (Table 5) .
Reporting of outcomes of benefit and harm in Cochrane plain language summaries
Among 94 (97.9%) Cochrane SRs reporting a patient-important outcome of benefit in their full-text, 43 (45.7%) explicitly reported the most patient-important outcome of benefit from the full-text in their plain language summary, 28 (29.8%) reported the outcome as an implicit statement, and 23 (24.5%) did not report the outcome in the summary (Table 6 ).
Among 68 (70.8%) Cochrane SRs reporting a patient-important outcome of harm in their full-text, 20 (29.4%) explicitly reported the most patient-important outcome of harm from the full-text in their plain language summary, 17 (25.0%) reported the outcome as an implicit statement, and 31 (45.6%) did not report the outcome in the summary (Table 6) .
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Discussion
Principal findings
Among 190 eligible SRs (96 Cochrane and 94 non-Cochrane) reporting dichotomuous outcomes, we found that authors frequently did not report the most patient-important outcomes of benefit and harm in their abstracts and plain language summaries. Authors seldom reported absolute measures of effect for either beneficial or harmful outcomes. These findings proved similar in Cochrane and non-Cochrane SRs.
Previous findings
The findings of our study are consistent with a structured review of general medical and public health journals that examined the frequency of absolute and relative measure reporting in health inequalities research [12] . Evaluating 344 articles published in 2009 among the top four general medicine and top four public health journals, the review found that only 138 reported numeric data in the abstract; among these, 88% reported a relative measure of effect, 9% reported only an absolute measure, and 2% reported both [12] . Similarly, an evaluation of 182 SR abstracts published in 2009, Beller and colleagues found that only 137 reported numeric data in the abstract; among these, 45 (25%) did not report an absolute or relative measure, and 87 (48%) reported only relative measures. In contrast, 28 (15%) abstracts reported only absolute measures, 14 (8%) reported data allowing both absolute and relative measures to be calculated, and only 8 (4%) reported both measures [9] .
Our study builds on the findings of these two studies, but focuses on patientimportant outcome reporting in Cochrane and non-Cochrane SRs published in 2010 across all medical and surgical fields. In line with their findings, we also found an overreliance on relative versus absolute measures in SR abstracts, and only a small number of SR abstracts that reported both types of measures.
Strengths and limitations
Our study has several strengths. We established explicit eligibility criteria, conducted sensitive searches to identify relevant data, and conducted eligibility screening and data abstraction independently and in duplicate with discussion to resolve discrepancies and establish consensus. We chose a large and representative sample of both Cochrane and non-Cochrane SRs, making the findings of our study broadly applicable. Unlike previous studies in the area [12] , our findings are not restricted to SRs from top journals. We assessed the reporting and presentation format of patient-important outcomes in abstracts, evaluating the use of absolute and relative measures and explicit and implicit statements, issues that have not been previously studied.
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Our study has several limitations. First, there was considerable judgment involved in many of the data abstracting decisions, in particular the judgment of outcomes of most importance. We did, however, provide extensive instructions, and conducted calibration exercises. Second, our search was limited to MEDLINE and the Cochrane Database of Systematic Reviews, which might limit the generalizability of our findings. It is, however, likely that non-MEDLINE indexed journals do no better than the MEDLINE-indexed journals we sampled.
Third, it may be that the quality of reporting has improved in recent years as a result of guidance from GRADE, and the Methodological Expectations of Cochrane Intervention Reviews (MECIR) project which encourage reporting of effect estimates in both relative and absolute effects. Further, the increased uptake of GRADE methodology and associated Summary of Findings table in SRs, particularly Cochrane SRs, is likely to have increased the use of absolute measures in SRs, and by extension, in their abstracts.
A 2012 study involving a cohort of Cochrane SRs showed that 45% of the SRs used the GRADE approach to interpret the overall quality of a body of evidence, versus only 6% of non-Cochrane SRs [13] . Considering the inclusion of GRADE as a surrogate of absolute estimates in the SR, we may estimate an approximate increase of 6% in absolute measure reporting in the SR over two years since our 2012 data. Given that it is very unlikely that non-Cochrane SRs have shown greater improvement than Cochrane SRs in the interval, it is unlikely that our study markedly underestimates reporting of absolute measures in the abstract.
Implications and future directions
Authors should, however, be careful in communicating the size of treatment effects. Assuming results, in relative terms, are significant: to calculate risk differences authors should ideally apply the relative estimate (eg, RR) to the baseline risk from welldesigned, large, observational studies. If such observational studies are not available, authors should consider the variation in the baseline risk among included studies in the SR. If there is little baseline variation, authors can use the median control group risk from the included studies. If large variation exists, authors can consider using two or more representative baseline risks from the included studies [14] .
For example, a meta-analysis of probiotics for the prevention of C. difficile infection included 21 RCTs, estimated a RR of 0.39, and observed baseline risks ranging from 0% to 40%, with a mean risk in control groups of 3.8% [15, 16] . Using the mean baseline risk of 3.8%, the RR of 0.39 corresponds to an ARR of 2.3% and a NNT of 43. Using the same RR of 0.39, based on the control group of the largest RCT to date M A N U S C R I P T
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(n=1488), the baseline risk of 1.2% corresponds to an ARR of 0.73% and an NNT of 137 [17] . In a second example drawn from an actual abstract: "patients randomized to primary percutaneous coronary intervention (PPCI) had lower mortality than did patients randomized to fibrinolysis (5.3% vs 7.9%, adjusted odds ratio 0.63, 95% CI 0.42-0.84, P < 0.001). The interaction between risk score and allocated treatment interaction term had no significant contribution (P = 0.52) to the model, indicating that the relative mortality reduction by PPCI was similar at all levels of estimated risk. In contrast, the absolute risk reduction was strongly related to estimated risk at baseline: the numbers needed to treat to prevent a death by PPCI versus fibrinolysis was 516 in the lowest quartile of estimated risk compared with only 17 in the highest quartile" [18] .
As illustrated above, the absolute size of the treatment effect can vary substantially depending on the baseline risk. In cases like the two described, reporting only the pooled mean ARR can be as uninformative or misleading as not reporting ARR at all, indicating that the assessment of the baseline risk in clinical decision-making is crucial [19, 20] .
Our findings suggest that major improvements in the reporting of absolute measures for patient-important outcomes in Cochrane and non-Cochrane SR abstracts are necessary. The PRISMA consensus statement on recommended items to include in the reporting of SRs and meta-analyses aims to promote transparency and complete reporting [21] . In its elaboration document, PRISMA encourages authors to report main results in the data synthesis section of their abstract, using numerical results with confidence intervals for the SR's most important outcomes, and ideally, with specifications of the numbers of studies and participants included in the analyses [22] . This is re-affirmed in the PRISMA for Abstracts Checklist published in 2013 [2] , which suggests that in addition to presenting the baseline risk, the presentation of results for the main outcomes of benefit and harm should include the number of studies and participants, summary measures, confidence intervals, direction of effect and size of effect (e.g., lower, fewer, reduced; greater, more, increased). With respect to absolute measures of effect, the PRISMA statement provides guidance (though somewhat limited): when a percentage is used, the baseline risk should also be shown, which allows the reader to see what the absolute benefit or harm is, and calculate whichever measures they choose. The guideline also suggests that results be presented in terms meaningful to clinicians and patients, including kilograms, days, and percentages [2] .
PRISMA for Abstracts does not, however, provide guidance to authors regarding the inclusion of the most patient important outcomes of benefit and harm, nor does it emphasize the need to report absolute measures of effect. The low proportions of SRs reporting patient-important outcomes and absolute measures is perhaps unsurprising in light of the guidance provided to authors of SRs.
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Conclusions
Strong, explicit guidance in authoritative reporting guidelines, such as those provided as part of the PRISMA abstract statement, should better address patientimportant outcome reporting with absolute measures of effect. To facilitate healthcare decision-making, journal editors should insist, in abstracts, that authors report all prespecified outcomes, which should include the most patient-important outcomes of benefit and harm in abstracts using absolute measures of effect. When interpreting research results based on abstract reporting, users of SRs should be aware of the merit of absolute effects for decision-making. 
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Mortality
-all cause mortality -disease specific mortality
Critically important
II
Morbidity
-cardiovascular major morbid events -other major morbid events (e.g. loss of vision, seizures, fracture, revascularization) -recurrence/relapse/remission of cancer/disease free survival -renal failure requiring dialysis 10 ( Non-Cochrane reviews (n = 94)
